TVGN | tickerfilter.com

Fundamental analysis

19%

Profitability 25%

Dept financing 25%

Liquidity 7%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.95%

1 Month

-9.43%

3 Months

-33.79%

6 Months

270.23%

1 Year

-59.15%

2 Year

-90.40%

Key data

Stock price

$0.96

P/E Ratio

1.14

DAY RANGE

$0.96 - $1.05

EPS

$0.04

52 WEEK RANGE

$0.26 - $3.09

52 WEEK CHANGE

-$60.82

MARKET CAP

62.866 M

YIELD

N/A

SHARES OUTSTANDING

170.647 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

-0.83

PUBLIC FLOAT

AVERAGE 10 VOLUME

$390,144

AVERAGE 30 VOLUME

$391,923

Company detail

CEO: Ryan Saadi
Region: US
Website: tevogen.com
Employees: 3
IPO year: 2022

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company was founded in 2020 and is based in Warren, New Jersey.

TVGN - Tevogen Bio Holdings Inc.